Search Results - "LUQMANI, R. A"

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by Yates, M, Watts, R A, Bajema, I M, Cid, M C, Crestani, B, Hauser, T, Hellmich, B, Holle, J U, Laudien, M, Little, M A, Luqmani, R A, Mahr, A, Merkel, P A, Mills, J, Mooney, J, Segelmark, M, Tesar, V, Westman, K, Vaglio, A, Yalçındağ, N, Jayne, D R, Mukhtyar, C

“…In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody…”
Get more information

Modification and validation of the Birmingham Vasculitis Activity Score (version 3) by Mukhtyar, C, Lee, R, Brown, D, Carruthers, D, Dasgupta, B, Dubey, S, Flossmann, O, Hall, C, Hollywood, J, Jayne, D, Jones, R, Lanyon, P, Muir, A, Scott, D, Young, L, Luqmani, R A

“…Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic…”
Get more information

2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides by Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., Flores‐Suarez, L. F., Gross, W. L., Guillevin, L., Hagen, E. C., Hoffman, G. S., Jayne, D. R., Kallenberg, C. G. M., Lamprecht, P., Langford, C. A., Luqmani, R. A., Mahr, A. D., Matteson, E. L., Merkel, P. A., Ozen, S., Pusey, C. D., Rasmussen, N., Rees, A. J., Scott, D. G. I., Specks, U., Stone, J. H., Takahashi, K., Watts, R. A.

Get full text

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force by Mukhtyar, C, Flossmann, O, Hellmich, B, Bacon, P, Cid, M, Cohen-Tervaert, J W, Gross, W L, Guillevin, L, Jayne, D, Mahr, A, Merkel, P A, Raspe, H, Scott, D, Witter, J, Yazici, H, Luqmani, R A

“…We undertook a systematic literature review as a background to the European League Against Rheumatism (EULAR) recommendations for conducting clinical trials in…”
Get more information

Nomenclature and classification of vasculitis – update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS) by Luqmani, R. A., Suppiah, R., Grayson, P. C., Merkel, P. A., Watts, R.

“…Summary Classification of vasculitis remains unsatisfactory. This is largely because the pathogenetic mechanisms of this family of related disorders have not…”
Get full text

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis by Flossmann, O, Baslund, B, Bruchfeld, A, Tervaert, J W Cohen, Hall, C, Heinzel, P, Hellmich, B, Luqmani, R A, Nemoto, K, Tesar, V, Jayne, D R W

“…Conventional therapy of Wegener's granulomatosis with cyclophosphamide and corticosteroids is limited by incomplete remissions and a high relapse rate. The…”
Get more information

Clinical features and structured clinical evaluation of vasculitis by Ponte, C., Águeda, A.F., Luqmani, R.A.

“…Systemic vasculitides are a group of heterogeneous conditions with overlapping patterns of clinical and laboratory manifestations. Moreover, clinical features…”
Get full text

Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis by ADU, D, PALL, A, LUQMANI, R. A, RICHARDS, N. T, HOWIE, A. J, EMERY, P, MICHAEL, J, SAVAGE, C. O. S, BACON, P. A

“…Although cyclophosphamide and prednisolone are effective in treating systemic vasculitis, the optimum treatment regimes and duration of treatment are unknown…”
Get full text

An approach to the diagnosis and management of systemic vasculitis by Miller, A., Chan, M., Wiik, A., Misbah, S. A., Luqmani, R. A.

“…Summary The systemic vasculitides are a complex and often serious group of disorders which, while uncommon, require careful management in order to ensure…”
Get full text

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis by Luqmani, R A, Bacon, P A, Moots, R J, Janssen, B A, Pall, A, Emery, P, Savage, C, Adu, D

“…The continuing morbidity of patients with vasculitis, despite the improved prognosis with aggressive therapy, underlines the need for accurate disease…”
Get more information

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis by Hellmich, Bernhard, Flossmann, Oliver, Gross, Wolfgang L, Bacon, Paul, Willem Cohen-Tervaert, Jan, Guillevin, Loic, Jayne, David, Mahr, Alfred, Merkel, Peter A, Raspe, Heiner, Scott, David G I, Witter, James, Yazici, Hasan, Luqmani, Raashid A

“…Objectives: To develop the European League Against Rheumatism (EULAR) recommendations for conducting clinical studies and/or clinical trials in systemic…”
Get full text

Towards diagnostic criteria for the ANCA-associated vasculitides by LUQMANI, R. A

Get full text

The diagnostic value of anti‐neutrophil cytoplasmic antibody testing in a routine clinical setting by McLaren, J.S., Stimson, R.H., McRorie, E.R., Coia, J.E., Luqmani, R.A.

“…Anti‐neutrophil cytoplasmic antibody (ANCA) tests are a routine clinical assay in most UK hospitals. We examined the role of routine ANCA testing in achieving…”
Get full text

Clinical and biological assessment in systemic necrotizing vasculitides by MUKHTYAR, C. B, FLOSSMANN, O, LUQMANI, R. A

“…The systemic vasculitides are multi-system disorders with significant mortality and morbidity and frequent relapses. Treatment is usually effective but fraught…”
Get full text

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials by Suppiah, Ravi, Hadden, Robert D. M., Batra, Rajbir, Arden, Nigel K., Collins, Michael P., Guillevin, Loic, Jayne, David R. W., Luqmani, Raashid A.

“…Objectives. To describe the incidence and prevalence of peripheral neuropathy in ANCA-associated vasculitis (AAV); to evaluate the correlation of neuropathy…”
Get full text

Damage occurs early in systemic vasculitis and is an index of outcome by EXLEY, A. R, CARRUTHERS, D. M, LUQMANI, R. A, KITAS, G. D, GORDON, C, JANSSEN, B. A, SAVAGE, C. O. S, BACON, P. A

“…Because death after acute systemic vasculitis is now uncommon, alternative measures of outcome are required. A significant component of patient morbidity is…”
Get full text

approach to the diagnosis and management of systemic vasculitis revised version with tracked changes removed by Miller, A, Chan, M, Wiik, A, Misbah, S.A, Luqmani, R.A

“…The systemic vasculitides are a complex and often serious group of disorders which, while uncommon, require careful management in order to ensure optimal…”
Get full text

Is it possible to offer evidence-based treatment for systemic vasculitis ? by LUQMANI, Raashid A

“…The evidence base for treatment of systemic vasculitis is reviewed in this article. Accurate diagnosis and evaluation of disease status is crucial to the…”
Get full text

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? by Flossmann, O, Jones, R B, Jayne, D R W, Luqmani, R A

“…Current standard immunosuppressive treatment reduces mortality substantially, but a large proportion of patients, particularly those with WG, follow a…”
Get full text

Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides by Exley, A R, Bacon, P A, Luqmani, R A, Kitas, G D, Gordon, C, Savage, C O, Adu, D

“…To develop and validate the Vasculitis Damage Index (VDI) for the standardized clinical assessment of damage in the systemic vasculitides. Using a nominal…”
Get more information